Glycated Albumin Assay Market, by Product Type (Human Glycated Albumin Assay and Animal Glycated Albumin Assay), by Application (Diagnostics (Prediabetes, Type 1 Diabetes, and Type 2 Diabetes) and Research), by End User (Hospital, Diagnostic Centers, Rese

Glycated Albumin Assay Market, by Product Type (Human Glycated Albumin Assay and Animal Glycated Albumin Assay), by Application (Diagnostics (Prediabetes, Type 1 Diabetes, and Type 2 Diabetes) and Research), by End User (Hospital, Diagnostic Centers, Research Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Glycated albumin assay is used in the clinical management of diabetes, which measures and monitors the glycated serum proteins (glycated albumin). Glycated albumin assay is point-of-care test offering various advantages over the conventional diagnostic techniques for diagnosis of diabetes, and which makes it cost-effective and reliable over conventional assay techniques.
Market Dynamics
There are various laboratory tests such as glycated hemoglobin (A1C), fasting plasma glucose (FG), and two-hour plasma glucose (2hG) used to diagnose diabetes mellitus. Glycated hemoglobin (A1C) assay is another major laboratory reference test for glycemic monitoring in diagnosis of diabetes mellitus (DM). However, glycated hemoglobin (A1C) assay is not recommended in certain clinical conditions, as it influences hemoglobin metabolism. Increased hemoglobin metabolism results in high glycation of proteins in the body, which represents biochemical abnormality in the body. To overcome this issues, many research institutes and laboratories are adopting glycated albumin assay as laboratory test for diagnosing DM. Moreover, GA assay have gained significant traction in last decade due to its advantages and benefits over glycated hemoglobin assay.
Glycated assay dose not influenced by the concentration of other serum proteins, as it is specific to albumin glycation rates. Moreover, the test does not require fasting conditions to measure and reflects the short term glycemia, due to half life time of albumin. Unlike glycated hemoglobin assay, the presence of hemolytic processes and abnormal Hb in body the does not alter the functioning of GA assay. Furthermore, glycated albumin assay have proven to be more effective marker than glycated hemoglobin assay in conditions such as anemia, pregnancy, postprandial hyperglycemia, and DM
Thus, advantages of glycated albumin assay are expected to drive growth of the global glycated albumin assay market over the forecast period.
Key features of the study:
This report provides in-depth analysis of the global glycated albumin assay market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrixes for this market
This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles leading players in the global Glycated Albumin Assay Market based on the following parameters – company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Asahi Kasei Corporation, Diazyme Laboratories, Inc., LifeSpan BioSciences, Inc., Biomatik Corporation, Abbexa Ltd., Geno Technology, Inc., DRG International, Inc., AMS Biotechnology (Europe) Limited, Abnova Corporation, Ethos Biosciences, Inc., Epinex Diagnostics Inc., DxGen Corp., and PathShodh Healthcare Private Limited
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, governmental initiatives, technological up-gradation, market expansions, and marketing tactics
The global Glycated Albumin Assay Market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the global ophthalmic viscoelastic devices industry, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Glycated Albumin Assay Market, By Product Type:
Human Glycated Albumin Assay
Animal Glycated Albumin Assay
Global Glycated Albumin Assay Market, By Application:
Diagnostics
Prediabetes
Type 1 Diabetes
Type 2 Diabetes
Research
Global Glycated Albumin Assay Market, By End User:
Hospital
Diagnostic Centers
Research Centers
Others
Global Glycated Albumin Assay Market, By Region:
North America
By Product Type:
Human Glycated Albumin Assay
Animal Glycated Albumin Assay
By Application:
Diagnostics
Prediabetes
Type 1 Diabetes
Type 2 Diabetes
Research
By End User
Hospital
Diagnostic Centers
Research Centers
Others
By Country:
U.S.
Canada
Europe
By Product Type:
Human Glycated Albumin Assay
Animal Glycated Albumin Assay
By Application:
Diagnostics
Prediabetes
Type 1 Diabetes
Type 2 Diabetes
Research
By End User
Hospital
Diagnostic Centers
Research Centers
Others
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Product Type:
Human Glycated Albumin Assay
Animal Glycated Albumin Assay
By Application:
Diagnostics
Prediabetes
Type 1 Diabetes
Type 2 Diabetes
Research
By End User
Hospital
Diagnostic Centers
Research Centers
Others
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific

Latin America
By Product Type:
Human Glycated Albumin Assay
Animal Glycated Albumin Assay
By Application:
Diagnostics
Prediabetes
Type 1 Diabetes
Type 2 Diabetes
Research
By End User
Hospital
Diagnostic Centers
Research Centers
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
By Product Type:
Human Glycated Albumin Assay
Animal Glycated Albumin Assay
By Application:
Diagnostics
Prediabetes
Type 1 Diabetes
Type 2 Diabetes
Research
By End User
Hospital
Diagnostic Centers
Research Centers
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type:
Human Glycated Albumin Assay
Animal Glycated Albumin Assay
By Application:
Diagnostics
Prediabetes
Type 1 Diabetes
Type 2 Diabetes
Research
By End User
Hospital
Diagnostic Centers
Research Centers
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Asahi Kasei Corporation
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Diazyme Laboratories, Inc
LifeSpan BioSciences, Inc.
Biomatik Corporation
Abbexa Ltd
Geno Technology, Inc.
DRG International, Inc
AMS Biotechnology (Europe) Limited
Abnova Corporation
Ethos Biosciences, Inc.
Epinex Diagnostics Inc.
DxGen Corp.
PathShodh Healthcare Private Limited
“*” marked represents similar segmentation in other categories in the respective section